Larissa S. Carnevalli

Feb 24, 2024 | nature.com | Adina M. Hughes |Nathan Standifer |Scott Hoffmann |Larissa S. Carnevalli |Fernando J. Calero-Nieto |Andrew Pierce | +9 more

AbstractThe Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here we show that modelling of intermittent ceralasertib treatment in mouse tumor models reveals CD8+ T-cell dependent antitumor activity, which is separate from the effects on tumor cells.

Feb 24, 2024 | nature.com | Adina M. Hughes |Nathan Standifer |Scott Hoffmann |Larissa S. Carnevalli |Fernando J. Calero-Nieto |Andrew Pierce | +9 more

AbstractThe Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here we show that modelling of intermittent ceralasertib treatment in mouse tumor models reveals CD8+ T-cell dependent antitumor activity, which is separate from the effects on tumor cells.

Aug 18, 2023 | nature.com | Lorna Hopcroft |Stuart Williamson |Susana Ros |Larissa S. Carnevalli |Elza DeBruin

Correction to: npj Breast Cancer https://doi.org/10.1038/s41523-023-00571-w, published online 05 August 2023In this article the author name Scott Hoffmann, was incorrectly written as Scott Hoffman. The original article has been corrected.

Aug 5, 2023 | nature.com | Stuart Williamson |Susana Ros |Lorna Hopcroft |Larissa S. Carnevalli |Elza DeBruin

Cell culture and reagentsAll cell lines were authenticated using DNA fingerprinting short-tandem repeat (STR) assays. To generate resistant cell populations, parental cell lines were exposed to escalating concentrations of palbociclib over 4–6 months. T47D cells were cultured up to a final dose of 3 μM, which generated two PalboR cell pools (named T47D RB− & T47D CDK6H).